Literature DB >> 17947705

Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase.

Janelle C Arthur1, John D Lich, Ramy K Aziz, Malak Kotb, Jenny P-Y Ting.   

Abstract

Monarch-1/NLRP12 is expressed in myeloid cells and functions as a negative regulator of inflammation by inducing proteasome-mediated degradation of NF-kappaB-inducing kinase. Monarch-1 is a member of the CATERPILLER gene family, also known as the nucleotide-binding domain leucine-rich repeat gene family. This family shares strong structural homology to major immune regulators expressed in lower organisms, including plants. In plants, these disease-resistance proteins (R proteins) sense pathogenic insult and initiate a protective response to limit pathogen growth. To perform this role, many R proteins require the highly conserved chaperone molecule, heat shock protein (Hsp) 90. Using a two-dimensional gel/mass spectrometry system, we detected the association of the nucleotide-binding domain leucine-rich repeat protein Monarch-1 with heat shock proteins. Further analysis indicates that analogous to plant R proteins, Hsp90 is required for Monarch-1 activity. In human monocytes, Monarch-1 associates with Hsp90, and these complexes are sensitive to treatment with specific Hsp90 inhibitors. Disruption of these complexes results in rapid degradation of Monarch-1 via the proteasome and prevents Monarch-1-induced proteolysis of NF-kappaB-inducing kinase. This demonstrates that Hsp90 is a critical regulator of Monarch-1 anti-inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947705     DOI: 10.4049/jimmunol.179.9.6291

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 2.  Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation.

Authors:  Sujatha Muralidharan; Pranoti Mandrekar
Journal:  J Leukoc Biol       Date:  2013-08-29       Impact factor: 4.962

3.  Heat shock protein 90 regulates IκB kinase complex and NF-κB activation in angiotensin II-induced cardiac cell hypertrophy.

Authors:  Kyung Hye Lee; Yangsoo Jang; Ji Hyung Chung
Journal:  Exp Mol Med       Date:  2010-10-31       Impact factor: 8.718

Review 4.  Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy.

Authors:  Nagathihalli S Nagaraj; Om V Singh; Nipun B Merchant
Journal:  Expert Rev Proteomics       Date:  2010-08       Impact factor: 3.940

Review 5.  Inflammasomes and their activation.

Authors:  Sonal Khare; Nancy Luc; Andrea Dorfleutner; Christian Stehlik
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 6.  The inflammasome NLRs in immunity, inflammation, and associated diseases.

Authors:  Beckley K Davis; Haitao Wen; Jenny P-Y Ting
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

7.  The NLRP12 pyrin domain: structure, dynamics, and functional insights.

Authors:  Anderson S Pinheiro; Clarissa Eibl; Zeynep Ekman-Vural; Robert Schwarzenbacher; Wolfgang Peti
Journal:  J Mol Biol       Date:  2011-09-28       Impact factor: 5.469

Review 8.  Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Authors:  Gary E L Brandt; Brian S J Blagg
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 9.  Sensing pathogens and danger signals by the inflammasome.

Authors:  Joao H F Pedra; Suzanne L Cassel; Fayyaz S Sutterwala
Journal:  Curr Opin Immunol       Date:  2009-02-14       Impact factor: 7.486

Review 10.  Modulating inflammation through the negative regulation of NF-κB signaling.

Authors:  Daniel E Rothschild; Dylan K McDaniel; Veronica M Ringel-Scaia; Irving C Allen
Journal:  J Leukoc Biol       Date:  2018-02-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.